INVO Bioscience, Inc.
INVO
$2.04
$0.2111.48%
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 5.77M | 4.25M | 3.02M | 1.92M | 1.18M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.77M | 4.25M | 3.02M | 1.92M | 1.18M |
| Cost of Revenue | 3.18M | 2.55M | 1.93M | 1.28M | 950.30K |
| Gross Profit | 2.59M | 1.70M | 1.09M | 634.70K | 227.10K |
| SG&A Expenses | 7.20M | 6.60M | 7.49M | 8.30M | 9.36M |
| Depreciation & Amortization | 619.40K | 408.80K | 200.90K | 79.20K | 78.40K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.01M | 9.66M | 9.79M | 9.89M | 10.79M |
| Operating Income | -5.24M | -5.41M | -6.77M | -7.98M | -9.62M |
| Income Before Tax | -7.06M | -7.05M | -8.01M | -8.80M | -10.10M |
| Income Tax Expenses | 26.70K | 29.60K | 27.80K | 6.90K | 5.00K |
| Earnings from Continuing Operations | -7.08 | -7.08 | -8.03 | -8.81 | -10.11 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.08M | -7.08M | -8.03M | -8.81M | -10.11M |
| EBIT | -5.24M | -5.41M | -6.77M | -7.98M | -9.62M |
| EBITDA | -4.62M | -5.00M | -6.57M | -7.90M | -9.54M |
| EPS Basic | -2.38 | -4.82 | -8.50 | -12.41 | -15.90 |
| Normalized Basic EPS | -1.36 | -2.88 | -5.25 | -7.75 | -9.93 |
| EPS Diluted | -2.38 | -4.82 | -8.50 | -12.41 | -15.90 |
| Normalized Diluted EPS | -1.36 | -2.88 | -5.25 | -7.75 | -9.93 |
| Average Basic Shares Outstanding | 12.31M | 9.43M | 6.25M | 3.74M | 2.57M |
| Average Diluted Shares Outstanding | 12.31M | 9.43M | 6.25M | 3.74M | 2.57M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
